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Purpose: Elderly patients (pts) (EPs; ≥ 65 years old) with newly diagnosed-acute 
decompensated heart failure (ND-ADHF) have not yet been studied. The aim of the 
present study was to investigate clinical characteristics, including echocardiograph-
ic findings and prognosis, for EPs with ND-ADHF and to compare those with non-
elderly pts (NEPs). Materials and Methods: We retrospectively investigated 256 
pts (144 males, 63.0 ± 14.8 years old) who were admitted to our hospital between 
January 2005 and March 2009 with ND-ADHF. Clinical characteristics and echo-
cardiographic parameters were analyzed in EPs (n = 135, 58 males) and NEPs (n = 
121, 86 males). Results: In intergroup comparison, female gender, diabetes melli-
tus, previous stroke and hypertension were more common in EPs. Body mass index 
(22.3 ± 4.5 vs. 24.0 ± 4.4 kg/m2), estimated glomerular filtration rate (54.8 ± 24.3 
vs. 69.2 ± 30.7 mL/min/m2), C-reactive protein (28.5 ± 46.9 vs. 7.6 ± 11.6 mg/dL), 
hemoglobin (12.3 ± 2.1 vs. 13.6 ± 2.3 g/dL) and N-terminal pro-brain natriuretic 
peptide level (10,538.2 ± 10,942.3 vs. 6,771.0 ± 8,964.7 pg/mL) were significantly 
different (p < 0.05 for all). Early mitral inflow velocity to early diastolic mitral an-
nular velocity (E/E’) was significantly higher in EPs than in NEPs (21.2 ± 9.4 vs. 
18.0 ± 8.9, p < 0.05). During follow-up (44.7 ± 14.5 months), there were no signifi-
cant differences in in-hospital mortality, re-hospitalization and cardiovascular mor-
tality between EPs and NEPs (p = NS for all). Conclusion: EPs with ND-ADHF 
have different clinical characteristics and higher LV filling pressure when compared 
with NEPs. However, the clinical outcomes for NEPs with ND-ADHF are not nec-
essarily more favorable than those for EPs.
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INTRODUCTION
The population of the elderly (≥ 65 years old) is increasing worldwide. The inci-
dence and prevalence of congestive heart failure (CHF) escalates exponentially with 
age. In fact, CHF affects 6-10% of people over the age of 65, and acute decompen-
sated heart failure (ADHF) is the most common cause for hospitalization of elderly 
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NEPs. In-hospital mortality was defined as death from any 
cause which occurred during the index admission, and CV 
mortality was defined as death from refractory HF, myocar-
dial infarction or stroke. Re-hospitalization was determined 
as an unplanned admission during follow-up period due to 
HF aggravation, myocardial infarction or stroke.
　　　
Echocardiographic measurements
Comprehensive echocardiographic evaluations were per-
formed using commercially available equipment (Vivid 7, 
GE Vingmed ultrasound, Horten, Norway or Sonos 5500, 
Philips Medical System, Andover, Mass, USA) on all pa-
tients within 24 hours of admission. The left ventricular 
(LV) ejection fraction (EF) was determined using the modi-
fied Quinones method. The left atrial volume index (LAVI) 
was determined using the prolate ellipsoid formula as de-
scribed previously.11 Every study subject underwent pulsed-
wave Doppler evaluation of mitral inflow and tissue Dop-
pler image (TDI) and following variables were measured: 
early mitral inflow velocity (E), late mitral inflow velocity 
(A), and deceleration time (DT) of the E wave. Simultane-
ously, peak systolic mitral annulus velocity (S’) and early 
diastolic mitral annulus velocity (E’) were determined at 
the septal corner of the mitral annulus from the apical four-
chamber view and E/E’ was calculated. The mean of five 
measurements were analyzed. The index echocardiographic 
data were gathered and two experienced echocardiographers, 
who were unaware of patients’ clinical data, performed a 
post-hoc analysis. 
Laboratory measurements
At the time of admission, blood sample was acquired in all 
patients for routine chemistry test including N-terminal pro 
brain natriuretic peptide (NT-ProBNP). The blood samples 
for NT-proBNP were kept at the temperature of 4ºC and an-
alyzed using the electrochemiluminescence immunoassay 
method (Elecsys proBNP; Roche Diagnostics GmbH, Ba-
sel, Switzerland). Glomerular filtration rate (GFR) was esti-
mated using the Modification of Diet in Renal Disease for-
mula equation: 170 × (SCr)-0.999 × (age)-0.176 × (BUN)-0.170 × 
(albumin)0.318 × 0.762 (if female), where SCr is serum creat-
inine in mg/dL. 
Statistical analysis
Continuous data are expressed as mean values ± standard 
deviation (SD). Because the NT-proBNP distribution was 
positively skewed, we used log-transformed NT-proBNP 
patients (EPs).1,2 ADHF may result from new onset of ven-
tricular dysfunction or, more typically, exacerbation of chron-
ic heart failure symptoms.3 The socioeconomic burden of 
CHF in the elderly is already tremendous and is expected to 
increase as more adults survive to old age thanks to reduced 
mortality from coronary heart disease and stroke.4
The epidemiology and optimal management of ADHF in 
the elderly are thought to be different in many aspects from 
those of relatively younger patients.1 However, EPs are typ-
ically underrepresented in heart failure (HF) trials.5 Appli-
cation of data from middle-aged patients with ADHF to 
treatment and management of EPs cannot be justified. 
Moreover, EPs who were investigated in previous CHF 
studies showed very diverse disease courses and heteroge-
neous chronicity.6-9 Accordingly, the clinical characteristics 
of with newly diagnosed-ADHF (ND-ADHF) in the elder-
ly remain to be determined.
The aims of the present study were to clarify the initial 
clinical presentation, echocardiographic parameters and 
prognosis of EPs with ND-ADHF, and to compare with 
those of non-EPs (NEPs, < 65 years old).
MATERIALS AND METHODS
Patient characteristics
This is a single center, retrospective and observational 
study. Study approval was obtained from the Institutional 
Review Board of Yonsei University College of Medicine. 
Between January 2005 and March 2009, 464 patients with 
ADHF were admitted to Yonsei Cardiovascular Hospital 
(Seoul, Republic of Korea). Among them, 256 patients 
were diagnosed as ND-ADHF and were investigated in this 
study. We defined ND-ADHF as “the first” presentation of 
having symptoms and showing signs of ADHF in patients 
who had no medical history of CHF before admission. The 
diagnosis of HF was made according to ACC/AHA 2005 
guidelines.10 Admission routes were via either outpatient 
department (OPD) or emergency room (ER). Chronic kid-
ney disease (CKD) was defined as a glomerular filtration 
rate (GFR) < 60 mL/min/1.73 m2, according to the Modifi-
cation of Diet in Renal Disease formula, or as requiring he-
modialysis on a regular basis. All patients were managed 
by experienced cardiologists. Clinical outcomes including 
in-hospital mortality, re-hospitalization due to HF aggrava-
tion and cardiovascular (CV) mortality during follow-up 
period were investigated and compared between EPs and 
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difference in follow-up duration between EPs and NEPs 
(44.9 ± 14.6 months vs. 44.4 ± 14.5 months, p = 0.799). In-
terestingly, there were no significant differences in re-hos-
pitalization rate (31.1% vs. 32.2%, p = 0.922) and CV mor-
tality (14.1% vs. 11.6%, p = 0.567) between EPs and NEPs 
during follow-up (Figs. 1 and 2). 
DISCUSSION
The principal findings of this study were that 1) female 
gender, DM, previous stroke and hypertension were more 
common in EPs; 2) less dilated LV with higher LVFP was 
noted in EPs; 3) clinical outcomes, including in-hospital 
mortality, re-hospitalization and CV mortality, were similar 
between the two groups during follow-up. 
HF is primarily a disease of the elderly. Approximately 
80% of patients hospitalized with ADHF are 65 years old 
or older.7,12 However, there is not enough data to clarify the 
clinical and echocardiographic characteristics of ADHF di-
agnosed for the first time in the elderly. The optimal thera-
peutic strategies for those EPs also remain to be deter-
mined.13 The results of the present study tell us that initial 
clinical presentation and echocardiographic findings of EPs 
with ND-ADHF may be different from those of NEPs. 
These factors should thus be considered when we treat EPs 
with ND-ADHF. 
In this study, ND-ADHF of EPs was more common in 
women. EPs were also leaner than NEPs. Several studies 
have found a strong inverse relationship between indices of 
obesity and subsequent clinical prognosis for patients with 
HF.14,15 According to previous reports, prognosis of HF is 
particularly grave in EPs complicated by the presence of 
multiple co-morbidities.16,17 Our study group shows that 
DM, hypertension and previous stroke are more prevalent 
in EPs with ND-ADHF than NEPs. Moreover, renal func-
tion in EPs, assessed by estimated GFR (eGFR), was sig-
nificantly poorer than in NEPs. Poor renal function itself is 
not only a poor prognostic factor for ADHF but also a cru-
cial problem hindering proper management of HF, because 
controlling overloaded body fluid volume in ADHF patient 
is mandatory. In treatment of ADHF patients with renal 
dysfunction, drug response is not optimal and the need for 
renal replacement treatment is increased. Consequently, 
timely and effective treatment is difficult, and there are more 
chances of complications such as infection, hemorrhage 
and thrombosis in EPs with ND-ADHF. 
values in statistical analysis. The baseline characteristics of 
the two groups were compared using the unpaired Student 
t-test for continuous variables, and the Chi-square test for 
categorical variables. Kaplan-Meier tests were used to ana-
lyze clinical outcomes in the two groups. Statistical data 
were processed by SPSS (Window Release 13.0; SPSS Inc, 
Chicago, IL, USA). A two-tailed p value of < 0.05 was con-
sidered significant.
RESULTS
Clinical characteristics and laboratory findings
The initial clinical characteristics with intergroup compari-
son data are provided in Table 1. Female gender, diabetes 
mellitus (DM), previous stroke and hypertension were more 
common in EPs. Admission via ER was more frequent in 
NEPs. The mean body mass index of EPs was significantly 
lower than that of NEPs. The length of hospital stay was 
not significantly different between the two groups. The in-
cidence of ADHF originating from ischemic heart disease 
was more prevalent in EPs. Significant differences were ob-
served in eGFR, NT-proBNP, hemoglobin and high-sensi-
tivity C-reactive protein (hsCRP) between EPs and NEPs 
(p < 0.05 for all). There was no significant difference in 
medications prescribed upon discharge between two groups.
Echocardiographic findings
Table 2 shows the initial echocardiographic parameters for 
enrolled patients with intergroup comparison data. Mean 
LVEF and LAVI were slightly higher in EPs than NEPs, 
but the differences between the two groups were statistical-
ly insignificant. However, E’ and S’, which reflect the myo-
cardial properties of relaxation and contraction respectively, 
were significantly lower in EPs as compared with those in 
NEPs. The mean DT of the E wave velocity was signifi-
cantly longer in EPs than in NEPs. Additionally, E/E’, 
which reflects end-diastolic LV filling pressure (LVFP), 
was significantly higher in EPs compared with NEPs. 
Clinical outcomes
Among the study population, in-hospital death occurred in 
20 patients (10 EPs and 10 NEPs, time to death ranging 
from 1 day to 58 days). In-hospital mortality rates between 
EPs and NEPs were not significantly different (7.4% vs. 
8.3%, p = 0.820). The mean follow-up period for the entire 
study population was 44.7 ± 14.5 months. There was no 
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Table 1. Intergroup Comparison of Clinical Characteristics and Laboratory Findings 
 EPs (n = 135) NEPs (n = 121) p value
Demographic characteristics
Age (yrs) 74.0 ± 6.9  50.6 ± 10.8 < 0.001*
Sex (male : female) 58 : 77  86 : 35 < 0.001*
BMI (at admission) (kg/m2) 22.3 ± 4.5 24.0 ± 4.4   0.003*
ER admission (n, %) 72 (53) 100 (83)   0.016*
LOS (days) 14.6 ± 34.8  11.7 ± 17.8 0.400
Etiology of ADHF   0.015*
    Idiopathic DCMP (n, %) 33 (24) 44 (36)   0.045*
    Valvular (n, %) 20 (16) 18 (15) 0.843
    Ischemic (n, %) 55 (41) 27 (22)   0.002*
    Hypertensive (n, %) 11 (8) 8 (7) 0.640
    Others (n, %) 15 (11) 24 (20) 0.078
DM (n, %) 45 (33) 26 (21)   0.035*
Hypertension (n, %) 76 (56) 51 (42)   0.024*
Dyslipidemia (n, %) 11 (8) 12 (10) 0.621
CKD (n, %) 36 (27) 21 (17) 0.074
Previous stroke (n, %) 22 (16) 9 (7)   0.030*
Previous myocardial infarction (n, %) 33 (24) 28 (23) 0.087
Atrial fibrillation (n, %) 61 (45) 45 (37) 0.195
Laboratory findings
eGFR (mL/min/1.73m2) 54.8 ± 24.3  69.2 ± 30.7   0.002*
NT-proBNP (pg/mL) 10,538.2 ± 109,42.3  6,771.0 ± 8,964.7   0.007*
Ln (NT-proBNP) 8.6 ± 1.4  8.0 ± 1.5   0.001*
Hemoglobin (g/dL) 12.3 ± 2.1 13.6 ± 2.3   0.001*
Homocysteine (µmol/L) 17.9 ± 8.3 15.3 ± 7.5 0.302
High sensitive C-reactive protein (mg/L) 28.5 ± 46.9    7.6 ± 11.6   0.001*
BUN (mg/dL) 24.9 ± 13.3  23.2 ± 16.4 0.351
Creatinine (mg/dL) 1.66 ± 1.82  1.80 ± 2.46 0.596
Glucose (mg/dL) 163.1 ± 107.6 143.0 ± 74.1 0.179
Uric acid (mg/dL) 6.2 ± 2.3  6.7 ± 2.5 0.328
Cholesterol (mg/dL) 148.3 ± 38.2 158.4 ± 40.9 0.187
Triglyceride (mg/dL) 94.4 ± 37.9 118.0 ± 69.9 0.152
HDL-cholesterol (mg/dL) 39.7 ± 6.7  39.6 ± 12.4 0.976
LDL-cholesterol (mg/dL) 98.5 ± 33.6   99.9 ± 34.7 0.871
Albumin (mg/dL) 3.8 ± 0.5  4.0 ± 0.5 0.116
Medications at discharge
Antiplatelet agents (n, %) 75 (56) 65 (54) 0.438
Anticoagulants (n, %) 40 (30) 42 (35) 0.556
Diuretics (n, %) 101 (75) 89 (74) 0.314
ACEis (n, %) 67 (50) 60 (50) 0.666
ARBs (n, %) 32 (24) 25 (21) 0.416
Beta-blockers (n, %) 57 (42) 51 (42) 0.708
Calcium channel blockers (n, %) 22 (16) 32 (26) 0.075
Digitalis (n, %) 55 (41) 50 (41) 0.796
Nitrates (n, %) 39 (29) 37 (31) 0.981
Statins (n, %) 44 (33) 43 (36) 0.843
EPs, elderly patients; NEPs, non-elderly patients; BMI, body mass index; ER, emergency room; LOS, length of hospital stay; ADHF, acute 
decompensated heart failure; DCMP, dilated cardiomyopathy; DM, diabetes mellitus; CKD, chronic kidney disease; eGFR, estimated 
glomerular filtration rate; NT-proBNP, N-terminal pro B-type natriuretic peptide; BUN, blood urea nitrogen; HDL, high density lipoprotein; 
LDL, low density lipoprotein; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker. 
*p < 0.05.
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dard biomarker for diagnosis and assessment of severity of 
HF. A significantly higher level of NT-proBNP in EPs sug-
gests that EPs with ND-ADHF present a higher initial LVFP, 
which in turn indicates a poorer prognosis.19
The echocardiographic findings were also meaningful. 
Although the LVEF was not different, EPs had fewer dilat-
ed LV chambers than NEPs. E/E’ was significantly higher 
and myocardial velocities including E’ and S’ were signifi-
cantly lower in EPs than in NEPs. Previous studies showed 
that noninvasive reliable echocardiographic parameters of 
E/E’ were positively correlated with invasive LVFP. These 
results mean that elevated LVFP is more problematic in 
EPs with ND-ADHF, as compared with NEPs.
Furthermore, EPs were more anemic and had significantly 
higher levels of hsCRP. Anemia and higher hsCRP are 
known to be ominous prognostic factors for HF. High hsCRP 
levels suggest that there could have been other co-morbid 
conditions such as inflammatory diseases in EPs. Plasma NT-
proBNP levels were also much higher in EPs. Both NT-
proBNP and BNP levels are known to increase with aging. 
Therefore, when we use NT-proBNP or BNP levels to diag-
nose CHF, age-dependent cutoff points should be considered. 
Plasma NT-proBNP level has been shown to be a biomarker 
for predicting LVFP in patients with HF.18 Although there are 
several limitations in the NT-proBNP based prediction of ele-
vated LVFP, NT-proBNP levels have been considered a stan-
Table 2. Intergroup Comparison of Echocardiographic Parameters 
EPs NEPs p value
LVEF (%) 34.5 ± 14.7 32.0 ± 15.9 0.208
LVEDD (mm) 57.6 ± 11.3 62.0 ± 10.9   0.003*
LVESD (mm) 48.1 ± 12.1 52.1 ± 12.7   0.014*
IVSD (mm) 10.1 ± 5.4 9.4 ± 2.2 0.215
PWD (mm) 9.6 ± 1.8 9.4 ± 2.3 0.652
LAVI (ml/m2) 52.0 ± 26.7 50.6 ± 31.4 0.731
E (cm/sec) 78.0 ± 26.1 86.4 ± 32.7 0.058
A (cm/sec) 38.6 ± 23.3 58.1 ± 24.6 0.313
DT (msec) 171.2 ± 48.9 150.1 ± 52.0   0.008*
S’ (cm/sec) 4.2 ± 1.5 4.7 ± 1.7   0.036*
E’ (cm/sec) 4.0 ± 1.3 5.2 ± 1.9 < 0.001*
A’ (cm/sec) 5.9 ± 1.9 5.8 ± 2.2 0.830
E/E’ 21.2 ± 9.4 18.0 ± 8.9   0.025*
LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; 
IVSD, interventricular septal dimension; PWD, posterior wall dimension; LAVI, left atrial volume index; E, peak velocity of early diastolic 
filling; A, peak velocity of late filling, DT, deceleration time of the E-wave velocity; S’, peak systolic mitral annular velocity; E’, early 
diastolic mitral annular velocity; A’, late diastolic mitral annular velocity; E/E’, early mitral inflow velocity to early diastolic mitral annular 
velocity ratio.
*p < 0.05.
Fig. 1. Kaplan-Meier event-free survival curve for re-hospitalization due to 
heart failure aggravation.
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Fig. 2. Kaplan-Meier event-free survival curve for cardiovascular mortality. 
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Interestingly, our study showed no differences in in-hos-
pital mortality, re-hospitalization and CV mortality between 
EPs and NEPs during follow-up. Our findings differ from 
previous knowledge regarding EPs with CHF. These results 
may be due to the small sample size of our study, but we 
suggest that our study provides information to important to 
understanding clinical features of EPs with ND-ADHF. In 
our opinion, age itself might not be a poor prognostic factor 
for CV mortality in patients with ND-ADHF. We think fur-
ther studies should be performed regarding the long-term 
prognosis of ND-ADHF in EPs.
This study has the following limitations: first, it was con-
ducted with a small sample population. Thus, only limited 
data analysis was possible, and we cannot exclude the pos-
sibility that the small sample size might be the cause of the 
unexpectedly favorable prognosis for EPs with ND-ADHF 
in this study. Second, our study was a single center retro-
spective investigation, so our analysis was limited to “se-
lected” patients. Finally, we used a noninvasive echocardio-
graphic parameter, E/E’, for the estimation of LVFP. We 
cannot neglect the discrepancy between E/E’ and direct-
measured LVFP. Moreover, direct comparison of E/E’ be-
tween EPs and NEPs might be limited, because E/E’ is 
known to decrease normally with age. 
In conclusion, EPs with ND-ADHF have different clini-
cal and echocardiographic parameters when compared with 
NEPs. Therefore, these characteristic findings can be taken 
into account when we initially manage EPs with ND-AD-
HF. The clinical outcomes of EPs with ND-ADHF may not 
be more unfavorable when compared with those of NEPs. 
Further studies are required to uncover the long-term prog-
nosis for ADHF and proper management strategies of EPs 
with ND-ADHF.
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